SILVER SPRINGS, NV / ACCESSWIRE / December 2, 2016 / Kasten, Inc. (KAST) announced today it has signed a letter of intent (LOI) to acquire formulas for Alzheimer's Disease and Erectile Dysfunction. The acquisition of the formulas will launch the Company into a broader portfolio of treatments for medical conditions outside of immediate urgent care.

"We are committed to providing solutions to medical conditions to extend quality of life. Alzheimer's disease is the only leading cause of death in the U.S. that has no therapies to prevent, cure or slow its progression. At $236 billion a year, it is also the most expensive disease in the U.S. We have an opportunity to make a difference for millions of people suffering daily," stated Jose Delgado, CEO of Kasten, Inc.

The Company is currently negotiating the terms of the definitive agreement with Gulf Coast Pharmaceutical, Inc. and is expected to close on the asset purchase within the next thirty days.

The Company also announced the resignation of Executive Chairman Michael Handley. "We are thankful to Mike for his assistance over these past couple of months as we now turn our sights onto raising the funds required to implement the opportunities we have put in place. We look forward to continuing to work with Mike and CHD to advance our directives," stated Jose Delgado, CEO of Kasten, Inc.

Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.

CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com

SOURCE: Kasten, Inc.